Citations

Mayo Clinic

Showing 10 of 108537 citations.

Perioperative anaphylaxis: updates on pathophysiology
Jordan, Justin T. , Levy, Jerrold H. , Gonzalez‐Estrada, Alexei , Jordan, Justin

Current Opinion in Allergy & Clinical Immunology | May 14, 2024 | Volume: 24 | Issue: 4 | Pages: 183-188

10.1097/aci.0000000000000994 | PMID 38743470 Get It

Purpose of review Perioperative anaphylaxis has historically been attributed to IgE/FcεRI-mediated reactions; there is now recognition of allergic and nonallergic triggers encompassing various reactions beyond IgE-mediated responses. This review aims to present recent advancements in knowledge regarding the mechanisms and pathophysiology of perioperative anaphylaxis. Recent findings Emerging evidence highlights the role of the mast-cell related G-coupled protein receptor X2 pathway in direct mast cell degranulation, shedding light on previously unknown mechanisms. This pathway, alongside traditional IgE/FcεRI-mediated reactions, contributes to the complex nature of anaphylactic reactions. Investigations into the microbiota-anaphylaxis connection are ongoing, with potential implications for future treatment strategies. While serum tryptase levels serve as mast cell activation indicators, identifying triggers remains challenging. A range of mediators have been associated with anaphylaxis, including vasoactive peptides, proteases, lipid molecules, cytokines, chemokines, interleukins, complement components, and coagulation factors. Summary Further understanding of clinical endotypes and the microenvironment where anaphylactic reactions unfold is essential for standardizing mediator testing and characterization in perioperative anaphylaxis. Ongoing research aims to elucidate the mechanisms, pathways, and mediators involved across multiple organ systems, including the cardiovascular, respiratory, and integumentary systems, which will be crucial for improving patient outcomes.
Neuro-Ophthalmic Literature Review
Bellows, David A., Chen, John J. , Cheng, Hui‐Chen , MacIntosh, Peter W., Vaphiades, Michael S., Chen, John J , McClelland, Collin M. , Zhang, Xiaojun

Neuro-Ophthalmology | May 14, 2024 | Volume: 48 | Issue: 3 | Pages: 218-226

10.1080/01658107.2024.2336786 Get It

Reply to “BASCULE syndrome: Additional evidence for the association with autonomic dysfunction”
Reinhart, Jacob P. , Kumar, Anagha , Rooke, Thom W. , Sartori‐Valinotti, Julio C. , Tollefson, Megha M. , Klaas, Kelsey , Davis, Dawn Marie R. , Kumar, Anagha Bangalore , Sartori-Valinotti, Julio C., Davis, Dawn M R , Reinhart, Jacob , Casanegra, Ana I.

Pediatric Dermatology | May 14, 2024 | Volume: 41 | Issue: 3 | Pages: 566-566

10.1111/pde.15549 | PMID 38743458 Get It

Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models
Jain, Sonia , Griffith, Jessica I. , Porath, Kendra A. , Rathi, Sneha , Le, Jiayan , Pasa, Tugce I. , Decker, Paul A. , Gupta, Shiv K. , Hu, Zeng , Carlson, Brett L. , Feldsien, Thomas M. , Lefebvre, Didier R. , Eckel‐Passow, Jeanette E. , Reilly, Edward B. , Elmquist, William F. , Bakken, Katrina K , Burgenske, Danielle M , Feldsien, Thomas M , Lefebvre, Didier R , Vaubel, Rachael A , Eckel-Passow, Jeanette E , Reilly, Edward B , Elmquist, William F , Sarkaria, Jann N , Gupta, Shiv K , Pasa, Tugce I , Jain, Sonia , Decker, Paul A. , Bakken, Katrina K. , Burgenske, Danielle M. , Vaubel, Rachael A. , Sarkaria, Jann N.

Clinical Cancer Research | May 14, 2024 | Volume: 30 | Issue: 15 | Pages: 3287-3297

10.1158/1078-0432.ccr-24-0426 | PMID 38743766 Get It

Abstract Purpose: Antibody-drug conjugates (ADC) are targeted therapies with robust efficacy in solid cancers, and there is intense interest in using EGFR-specific ADCs to target EGFR-amplified glioblastoma (GBM). Given GBM’s molecular heterogeneity, the bystander activity of ADCs may be important for determining treatment efficacy. In this study, the activity and toxicity of two EGFR-targeted ADCs with similar auristatin toxins, Losatuxizumab vedotin (ABBV-221) and Depatuxizumab mafodotin (Depatux-M), were compared in GBM patient-derived xenografts (PDX) and normal murine brain following direct infusion by convection-enhanced delivery (CED). Experimental Design: EGFRviii-amplified and non-amplified GBM PDXs were used to determine in vitro cytotoxicity, in vivo efficacy, and bystander activities of ABBV-221 and Depatux-M. Nontumor-bearing mice were used to evaluate the pharmacokinetics (PK) and toxicity of ADCs using LC-MS/MS and immunohistochemistry. Results: CED improved intracranial efficacy of Depatux-M and ABBV-221 in three EGFRviii-amplified GBM PDX models (Median survival: 125 to >300 days vs. 20–49 days with isotype control AB095). Both ADCs had comparable in vitro and in vivo efficacy. However, neuronal toxicity and CD68+ microglia/macrophage infiltration were significantly higher in brains infused with ABBV-221 with the cell-permeable monomethyl auristatin E (MMAE), compared with Depatux-M with the cell-impermeant monomethyl auristatin F. CED infusion of ABBV-221 into the brain or incubation of ABBV-221 with normal brain homogenate resulted in a significant release of MMAE, consistent with linker instability in the brain microenvironment. Conclusions: EGFR-targeting ADCs are promising therapeutic options for GBM when delivered intratumorally by CED. However, the linker and payload for the ADC must be carefully considered to maximize the therapeutic window.
Characteristics of emerging new autoimmune diseases after COVID‐19 vaccination: A sub‐study by the COVAD group
Shumnalieva, Russka , Ravichandran, Naveen , Javaid, Mahnoor , Darooka, Naitica , Gonzalez, Daniel E., Velikova, Tsvetelina , Milchert, Marcin , Kuwana, Masataka , Boyd, Peter , Yaadav, Praggya , Cheng, Karen Kow Yip , Kobert, Linda , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Parodis, Ioannis , Dey, Dzifa , Nikiphorou, Elena , Kadam, Esha , Tan, Ai Lyn , Chinoy, Hector , Gupta, Latika, Group, COVAD Study, Agarwal, Vikas , Tehozol, Erick Adrian Zamora , Gupta, Latika , Javaid, Mahnoor , Darooka, Naitica , Velikova, Tsvetelina , Milchert, Marcin , Kuwana, Masataka , Joshi, Mrudula , Gracia-Ramos, Abraham Edgar , Boyd, Peter , Yaadav, Praggya , Cheng, Karen , Cavagna, Lorenzo , Sen, Parikshit , Day, Jessica , Makol, Ashima , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Saha, Sreoshy , Parodis, Ioannis , Dey, Dzifa , Nikiphorou, Elena , Distler, Oliver , Kadam, Esha , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Knitza, Johannes , Chinoy, Hector , Aggarwal, Rohit , Agarwal, Vikas , Gupta, Latika , Agarwal, Vikas , Naveen, R , Zamora Tehozol, Erick Adrian , Shumnalieva, Russka , Hannah, Jennifer R. , Roy, Debaditya , Joshi, Mrudula , Gracia‐Ramos, Abraham Edgar , Sen, Parikshit , Day, Jessica , Makol, Ashima , Saha, Sreoshy , Distler, Oliver , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Aggarwal, Rohit , Group, COVAD Study

International Journal of Rheumatic Diseases | May 14, 2024 | Volume: 27 | Issue: 5 | Pages: No page available

10.1111/1756-185x.15178 | PMID 38742751 Get It

AbstractBackgroundDespite the overall safety and efficacy of COVID‐19 vaccinations, rare cases of systemic autoimmune diseases (SAIDs) have been reported post‐vaccination. This study used a global survey to analyze SAIDs in susceptible individuals' post‐vaccination.MethodsA cross‐sectional study was conducted among participants with self‐reported new‐onset SAIDs using the COVID‐19 Vaccination in Autoimmune Diseases (COVAD) 2 study dataset—a validated, patient‐reported e‐survey—to analyze the long‐term safety of COVID‐19 vaccines. Baseline characteristics of patients with new‐onset SAIDs and vaccinated healthy controls (HCs) were compared after propensity score matching based on age and sex in a 1:4 ratio.ResultsOf 16 750 individuals, 74 (median age 52 years, 79.9% females, and 76.7% Caucasians) had new‐onset SAID post‐vaccination, mainly idiopathic inflammatory myopathies (IIMs) (n = 23, 31.51%), arthritis (n = 15; 20.53%), and polymyalgia rheumatica (PMR) (n = 12, 16.40%). Higher odds of new‐onset SAIDs were noted among Caucasians (OR = 5.3; 95% CI = 2.9–9.7; p < .001) and Moderna vaccine recipients (OR = 2.7; 95% CI = 1.3–5.3; p = .004). New‐onset SAIDs were associated with AID multimorbidity (OR = 1.4; 95% CI = 1.1–1.7; p < .001), mental health disorders (OR = 1.6; 95% CI = 1.3–1.9; p < .001), and mixed race (OR = 2.2; 95% CI = 1.2–4.2; p = .010), where those aged >60 years (OR = 0.6; 95% CI = 0.4–0.8; p = .007) and from high/medium human development index (HDI) countries (compared to very high HDI) reported fewer events than HCs.ConclusionThis study reports a low occurrence of new‐onset SAIDs following COVID‐19 vaccination, primarily IIMs, PMR, and inflammatory arthritis. Identified risk factors included pre‐existing AID multimorbidity, mental health diseases, and mixed race. Revaccination was well tolerated by most patients; therefore, we recommend continuing COVID‐19 vaccination in the general population. However, long‐term studies are needed to understand the autoimmune phenomena arising post‐vaccination.
Insights into ALD and AUD diagnosis and prognosis: Exploring AI and multimodal data streams
Narayanan, Praveena , Wu, Tiffany , Shah, Vijay H. , Curtis, Brenda , Curtis, Brenda L , Wu, Tiffany

Hepatology | May 14, 2024 | Volume: 80 | Issue: 6 | Pages: 1480-1494

10.1097/hep.0000000000000929 | PMID 38743008 Get It

The rapid evolution of artificial intelligence and the widespread embrace of digital technologies have ushered in a new era of clinical research and practice in hepatology. Although its potential is far from realization, these significant strides have generated new opportunities to address existing gaps in the delivery of care for patients with liver disease. In this review, we discuss how artificial intelligence and opportunities for multimodal data integration can improve the diagnosis, prognosis, and management of alcohol-associated liver disease. An emphasis is made on how these approaches will also benefit the detection and management of alcohol use disorder. Our discussion encompasses challenges and limitations, concluding with a glimpse into the promising future of these advancements.
Multimodality imaging for acquired supravalvular aortic stenosis
Alsidawi, Said , Nkomo, Vuyisile T. , Wang, George, Nkomo, Vuyisile T , Alsidawi, Said , Lee, Kwan , Wang, George C.

European Heart Journal - Cardiovascular Imaging | May 14, 2024 | Volume: 25 | Issue: 10 | Pages: e254-e254

10.1093/ehjci/jeae128 | PMID 38742633 Get It

Letermovir for cytomegalovirus prophylaxis in lung transplant recipients: A promising shift toward reduced myelotoxicity
Alsharif, Muath, Pennington, Kelly M.

Transplant Infectious Disease | May 14, 2024 | Volume: 26 | Issue: 3 | Pages: No page available

10.1111/tid.14277 | PMID 38742608 Get It

Racial Disparities in Cardiovascular and Cerebrovascular Adverse Events in Patients with Non-Hodgkin Lymphoma: A Nationwide Analysis
Chandani, Kanishka Uttam, Agrawal, Siddharth , Raval, Maharshi , Siddiq, Sajid, Hashmi, Shahrukh K. , Agrawal, Siddharth Pravin , Nadeem, Ahmed , Chintakuntlawar, Ashish V.

Medicina | May 14, 2024 | Volume: 60 | Issue: 5 | Pages: 800

10.3390/medicina60050800 | PMID 38792983 Get It

Background and Objectives: Non-Hodgkin lymphoma (NHL) has the sixth-highest malignancy-related mortality in the United States (US). However, inequalities exist in access to advanced care in specific patient populations. We aim to study the racial disparities in major adverse cardiovascular and cerebrovascular events (MACCEs) in NHL patients. Materials and Methods: Using ICD-10 codes, patients with NHL were identified from the US National Inpatient Sample 2016–2019 database. Baseline characteristics, comorbidities, and MACCE outcomes were studied, and results were stratified based on the patient’s race. Results: Of the 777,740 patients with a diagnosis of NHL, 74.22% (577,215) were White, 9.15% (71,180) were Black, 9.39% (73,000) were Hispanic, 3.33% (25,935) were Asian/Pacific Islander, 0.36% (2855) were Native American, and 3.54% (27,555) belonged to other races. When compared to White patients, all-cause mortality (ACM) was significantly higher in Black patients (aOR 1.27, 95% CI 1.17–1.38, p < 0.001) and in Asian/Pacific Islander patients (aOR 1.27, 95% CI 1.12–1.45, p < 0.001). Sudden cardiac death was found to have a higher aOR in all racial sub-groups as compared to White patients; however, it was statistically significant in Black patients only (aOR 1.81, 95% CI 1.52–2.16, p < 0.001). Atrial fibrillation (AF) risk was significantly lower in patients who were Black, Hispanic, and of other races compared to White patients. Acute myocardial infarction (AMI) was noted to have a statistically significantly lower aOR in Black patients (0.70, 95% CI 0.60–0.81, p < 0.001), Hispanic patients (0.69, 95% CI 0.59–0.80, p < 0.001), and patients of other races (0.57, 95% CI 0.43–0.75, p < 0.001) as compared to White patients. Conclusions: Racial disparities are found in MACCEs among NHL patients, which is likely multifactorial, highlighting the need for healthcare strategies stratified by race to mitigate the increased risk of MACCEs. Further research involving possible epigenomic influences and social determinants of health contributing to poorer outcomes in Black and Asian/Pacific Islander patients with NHL is imperative.
Peripheral Venous Pressure+Fenestration Doppler=Noninvasive Cardiac Catheterization Post-Fontan
Miranda, William R. , Bruaene, Alexander Van De , Jain, C. Charles , Van De Bruaene, Alexander

Circulation: Heart Failure | May 14, 2024 | Volume: 17 | Issue: 5 | Pages: No page available

10.1161/circheartfailure.124.011562 | PMID 38742413 Get It